Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
49
AUPH Quote, Financials, Valuation and Earnings
Last price:
$13.95
Seasonality move
:
-3.35%
Day range:
$13.87 - $14.51
52-week range:
$6.83 - $16.54
Dividend yield:
0%
P/E ratio:
6.72x
P/S ratio:
6.84x
P/B ratio:
3.19x
Volume:
1M
Avg. volume:
984.1K
1-year change:
72.01%
Market cap:
$1.9B
Revenue:
$283.1M
EPS (TTM):
$2.08
Analysts' Opinion
-
Consensus RatingAurinia Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.00, Aurinia Pharmaceuticals, Inc. has an estimated upside of 21.86% from its current price of $13.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing 100% downside risk from its current price of $13.95.
Fair Value
-
According to the consensus of 7 analysts, Aurinia Pharmaceuticals, Inc. has 21.86% upside to fair value with a price target of $17.00 per share.
AUPH vs. S&P 500
-
Over the past 5 trading days, Aurinia Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.1% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aurinia Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aurinia Pharmaceuticals, Inc. has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Aurinia Pharmaceuticals, Inc. reported revenues of $77.1M.
Earnings Growth
-
Aurinia Pharmaceuticals, Inc. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Aurinia Pharmaceuticals, Inc. reported earnings per share of $1.53.
Enterprise value:
1.5B
EV / Invested capital:
2.33x
Price / LTM sales:
6.84x
EV / EBIT:
13.19x
EV / Revenue:
5.41x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
11.29x
Price / Operating cash flow:
14.26x
Enterprise value / EBITDA:
11.30x
Gross Profit (TTM):
$250.4M
Return On Assets:
50.28%
Net Income Margin (TTM):
29.28%
Return On Equity:
71.44%
Return On Invested Capital:
59.78%
Operating Margin:
36.52%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $175.5M | $235.1M | $283.1M | $59.9M | $77.1M | |
| Gross Profit | $160.6M | $206.9M | $250.4M | $54.3M | $68.3M | |
| Operating Income | -$83.3M | $14.1M | $116.1M | $9.2M | $28.2M | |
| EBITDA | -$71.5M | $33.5M | $135.5M | $14M | $33M | |
| Diluted EPS | -$0.55 | $0.04 | $2.08 | $0.01 | $1.53 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $513.3M | $442.5M | $424.8M | $446.6M | $492M | |
| Total Assets | $543.4M | $470.9M | $548.1M | $550.6M | $770.6M | |
| Current Liabilities | $40.6M | $46.1M | $77.2M | $97.8M | $93.7M | |
| Total Liabilities | $64.3M | $65.4M | $170.1M | $173.2M | $189.3M | |
| Total Equity | $479.1M | $405.4M | $378M | $377.5M | $581.3M | |
| Total Debt | $7.7M | $7.2M | $96.6M | $78.3M | $73.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.2M | $43.5M | $135.9M | $29.3M | $44.6M | |
| Cash From Investing | -$6.6M | $38.5M | -$32.8M | $38.4M | -$36.9M | |
| Cash From Financing | -$5.1M | -$48.1M | -$106.3M | -$22.1M | -$511.4K | |
| Free Cash Flow | -$33.9M | $43.2M | $135.7M | $29.2M | $44.5M | |
AUPH
Sector
Market Cap
$1.9B
$25.1M
Price % of 52-Week High
84.34%
48.72%
Dividend Yield
0%
0%
Shareholder Yield
4.07%
-1.6%
1-Year Price Total Return
72.01%
-18.38%
Beta (5-Year)
1.535
0.490
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$14.55
200-day SMA
Buy
Level
$12.56
Bollinger Bands (100)
Sell
Level
13.68 - 15.9
Chaikin Money Flow
Sell
Level
-157.8M
20-day SMA
Sell
Level
$14.42
Relative Strength Index (RSI14)
Sell
Level
41.48
ADX Line
Sell
Level
11.52
Williams %R
Neutral
Level
-75
50-day SMA
Sell
Level
$14.72
MACD (12, 26)
Sell
Level
-0.08
25-day Aroon Oscillator
Buy
Level
16
On Balance Volume
Neutral
Level
406.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.9957)
Buy
CA Score
(Annual)
Level (1.5311)
Sell
Beneish M-Score
(Annual)
Level (9.438)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.3321)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.
Stock Forecast FAQ
In the current month, AUPH has received 4 Buy ratings 3 Hold ratings, and 0 Sell ratings. The AUPH average analyst price target in the past 3 months is $17.00.
-
Where Will Aurinia Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aurinia Pharmaceuticals, Inc. share price will rise to $17.00 per share over the next 12 months.
-
What Do Analysts Say About Aurinia Pharmaceuticals, Inc.?
Analysts are divided on their view about Aurinia Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aurinia Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Aurinia Pharmaceuticals, Inc.'s Price Target?
The price target for Aurinia Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $17.00 according to 7 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is AUPH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aurinia Pharmaceuticals, Inc. is a Buy. 4 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AUPH?
You can purchase shares of Aurinia Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aurinia Pharmaceuticals, Inc. shares.
-
What Is The Aurinia Pharmaceuticals, Inc. Share Price Today?
Aurinia Pharmaceuticals, Inc. was last trading at $13.95 per share. This represents the most recent stock quote for Aurinia Pharmaceuticals, Inc.. Yesterday, Aurinia Pharmaceuticals, Inc. closed at $13.95 per share.
-
How To Buy Aurinia Pharmaceuticals, Inc. Stock Online?
In order to purchase Aurinia Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get AUPH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
AUPH
Sector
P/E ratio
6.72x
21.37x
PEG ratio
0.00x
-0.01x
P/B ratio
3.19x
1.73x
Price / LTM sales
6.84x
1.46x
Growth Metrics
AUPH
Sector
Revenue growth
28.81%
3.27%
Earnings growth
15628.87%
12.13%
Revenue (5-year growth)
41.38%
6.25%
Earnings forecast
$0.22
-$0.20
Profitability
AUPH
Sector
Profitability FY 2025
$250.4M
$2.3M
Return on invested capital
59.78%
-33.43%
Return on assets
50.28%
-29.94%
Return on equity
71.44%
-40.07%
Earnings Date
Last Earnings Date
Feb
26
Next Earnings Date
May
11
Estimated Next Earnings Date
May
28
Balance Sheet
AUPH
Sector
Total cash
$398M
$24.9M
Short term investments
$275M
$23M
Total assets
$770.6M
$70.1M
Long term debt
$73.7M
$2.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 34x
Sell
34
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
56
ORKA alert for Mar 15
Oruka Therapeutics, Inc. [ORKA] is up 16.04% over the past day.
Buy
100
APEI alert for Mar 15
American Public Education, Inc. [APEI] is up 26.24% over the past day.
Sell
40
GDXD alert for Mar 14
MicroSectors Gold Miners -3X Inverse Leveraged ETN [GDXD] is up 26.02% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
